Table 1.
Baseline patient characteristics
| FC (N = 60) | IBS-C (N = 33) | |
|---|---|---|
| Female, n (%) | 36 (60) | 24 (73) |
| Age in years, median (IQR) | 13.9 (12.6–16.2) | 15.8 (14.7–16.7) |
| Duration of symptoms in years, median (IQR)a | 5.8 (2.3–8.3) | 3.1 (1.2–4.6) |
| Surgical history | ||
| None, n (%) | 44 (73) | 30 (91) |
| Appendicostomy/cecostomy, n (%) | 9 (15) | 1 (3.0) |
| Sacral nerve stimulation, n (%) | 4 (6.7) | 1 (3.0) |
| Colonic resection, n (%) | 3 (5.0) | 0 (0) |
| Anal sphincter botulinum toxin injection, n (%) | 1 (1.7) | 2 (6.1) |
| Stoma, n (%) | 1 (1.7) | 0 (0) |
| Colonic motility, total tests | 23 | 3 |
| Normal, n (%) | 10 (43) | 1 (33) |
| Distal segmental dysmotility, n (%) | 12 (52) | 1 (33) |
| Generalized dysmotility, n (%) | 1 (4.3) | 1 (33) |
| Treatment before starting linaclotide | ||
| Oral laxatives, n (%) | 46 (77) | 25 (76) |
| Polyethylene glycol, n (%) | 22 (37) | 15 (46) |
| Senna, n (%) | 14 (23) | 9 (27) |
| Psyllium fiber, n (%) | 4 (6.7) | 1 (3.0) |
| Lactulose, n (%) | 4 (6.7) | 0 (0) |
| Milk of magnesia, n (%) | 2 (3.3) | 1 (3.0) |
| Lubiprostone, n (%) | 12 (20) | 13 (39) |
| Neuromodulators, n (%) | 10 (17) | 10 (30) |
| Hyoscyamine, n (%) | 3 (5.0) | 3 (9.1) |
| Serotonin reuptake inhibitor, n (%) | 3 (5.0) | 1 (3.0) |
| Dicycloverine, n (%) | 2 (3.3) | 2 (6.1) |
| Gabapentin, n (%) | 2 (3.3) | 1 (3.0) |
| Tricyclic antidepressant, n (%) | 0 (0) | 3 (9.1) |
| Antegrade continence enemas, n (%) | 8 (13) | 1 (3.0) |
| Rectal medication, n (%) | 5 (8.3) | 4 (12) |
| Bisacodyl enema PRN, n (%) | 3 (5.0) | 2 (6.1) |
| Mineral oil enema PRN, n (%) | 1 (1.7) | 1 (3.0) |
| Bisacodyl enema weekly, n (%) | 1 (1.7) | 0 (0) |
| Sodium fleet enema daily, n (%) | 0 (0) | 1 (3.0) |
| Sacral nerve stimulation, n (%) | 0 (0) | 0 (0) |
| Dose at start of linaclotide | ||
| 72 µg daily, n (%) | 10 (17) | 4 (12) |
| 145 µg daily, n (%) | 50 (83) | 28 (85) |
| 290 µg daily, n (%) | 0 (0) | 1 (3.0) |
FC functional constipation, IBS-C irritable bowel syndrome with constipation, PRN when necessary
aIncludes data of 44 children with FC and 25 children with IBS-C